Plasmakoncentrationerne af visse hiv- 1 proteasehæmmere, som overvejende metaboliseres af CYP3A4, kan øges ved samtidig administration af lavdosis ritonavir, som hæmmer denne metabolisering.
Plasma levels of certain HIV-1 protease inhibitors, which are metabolised predominantly by CYP3A4, can be increased by the co-administration of low-dose ritonavir, which is an inhibitor of this metabolism.